1. In Vivo
  2. >>Archive

Stryker Makes a Play as Disc Replacement Gets Ready to Boom

Stryker's recent acquisition of SpineCore represents just the latest move of a large orthopedics company into the promising field of disc replacement, a technology expected to boom over the next four years.

The announcement last month that Stryker Corp. has agreed to acquire - NJ-based SpineCore Inc. [See Deal] for an estimated $350 million makes the orthopedics giant the third company in the last eighteen months to place a bet on the promising field of disc replacement—and the third willing to pay handsomely for the opportunity--following similarly-sized deals by Synthes-Stratec for Spine Solutions Inc. [See Deal] and Johnson & Johnson 's DePuy AcroMed Inc. for Link Spine Group Inc. [See Deal], both in 2003. Whether disc replacement as a therapy justifies the more than $1 billion that these three deals have fetched remains to be seen. But there's no greater vote of confidence for a technology that has been a long time in coming.

As noted in US Markets for Adjunctive and Non-Fusion Spine Technologies, a report produced by Health Research International and distributed...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By Ashley Yeo

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.